Integra LifeSciences Reports Third Quarter 2026 Financial Results
Globe Newswire•21/10/2026•06:00 ET
0
Key Highlights
- ➤Q3 revenue $411.2 million, up 2.3% reported and 2.5% organically
- ➤Adjusted EPS $0.59, up from $0.54 year over year
- ➤Tissue Reconstruction revenue $107.1 million, down 2.2% reported and organically
- ➤$2.1 billion debt refinancing extends maturities and enhances financial flexibility
- ➤2026 revenue guidance $1.634 billion-$1.654 billion; adjusted EPS guidance $2.30-$2.40
Expert Statements
Stuart Essig, Chairman and Chief Executive Officer of Integra LifeSciences
“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing”
Stuart Essig, Chairman and Chief Executive Officer of Integra LifeSciences
“Our updated outlook reflects both the recovery timeline in Cincinnati and more measured expectations for portions of our Tissue Reconstruction business. We are focused on executing against these challenges while continuing to support our customers, advance key product launches and returns, and strengthen the business for more consistent long-term growth.”
PRINCETON, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2026.
Third Quarter 2026 Highlights * Third quarter revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year. Results included an approximate $7 million revenue impact related to flood damage at the Company’s Cincinnati facility.
Get started
Create a free account to read the full story.